Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain  by Geleijnse, Marcel L. et al.
JACC Vol. 28, No. 2 447 
August 1996:447-54 
Prognostic Value of Dobutamine-Atropine Stress Technetium-99m 
Sestamibi Perfusion Scintigraphy in Patients With Chest Pain 
MARCEL L. GELEIJNSE, MD, ABDOU ELHENDY, MD, PHD, RON T. VAN DOMBURG, MS¢, 
JAN H. CORNEL, MD, AMBROOS E. M. REIJS, MSc, JOS R. T. C. ROELANDT, MD, PHD, FACC, 
ERIC P. KRENNING, MD, PIaD, PAOLO M. FIORETTI, MD, PHD, FACC 
Rotterdam, The Netherlands 
Objectives. This study investigated the prognostic value of 
dobutamine-atropine technetium-99m (Tc-99m) sestamibi single- 
photon emission computed tomographic (SPECT) myocardial 
perfusion imaging. 
Background. Dobutamine-atropine Tc-99m sestamibi SPECT 
imaging is an accurate method for the detection of coronary 
disease. However, the prognostic value of this stress modality has 
not been assessed. 
Methods. Three hundred ninety.two consecutive patients with 
chest pain (mean [-+SD] age 60 + 12 years; 220 men, 190 with a 
previous myocardial infarction) underwent a dobutamine- 
atropine Tc-99m sestamibi SPECT scintigraphic study. Patients 
were followed up for 22 -+ 13 months to determine the univariate 
and multivariate variables associated with hard cardiac events 
(cardiac death, nonfatal myocardial infarction), to define their 
event-free survival and to determine whether the extent and 
severity of reversible perfusion defects correlated with events. 
Results. Forty-four patients (11%) had hard cardiac events. 
Multivariate models demonstrated that older age (odds ratio 
[OR] 2.1, 95% confidence interval [CI] 1.0 to 4.4), history of heart 
failure (OR 2.6, 95% CI 1.3 to 5.2), abnormal sestamibi scan 
results (OR 10.0, 95% CI 2.3 to 43.0) and reversible perfusion 
defects (OR 3.2, 95% CI 1.6 to 6.4) had independent predictive 
value. Patients without perfusion defects, with fixed defects alone, 
reversible defects alone and fixed plus reversible defects had 
annual hard cardiac event rates of 0.8%, 6.8%, 8.1% and 11.6%, 
respectively. Patients with increasing reversible defect scores had 
increasing annual event rates of 2.1%, 5.0%, 5.5%, 13.0% and 
14.6%, respectively. 
Conclusions. Dobntamine-atropine stress Tc-99m sestamibi 
SPECT imaging provides excellent prognostic information. The 
single most important independent predictor for future hard 
cardiac events is an abnormal pattern, and a reversible defect 
provides additional, independent prognostic information. More- 
over, the extent and severity of reversible defects are major 
determinants for prognosis. 
(J Am Coil Cardiol 1996;28:447-54) 
Exercise testing provides important diagnostic and prognostic 
information in patients with known or suspected coronary 
artery disease (1). Addition of teehnetium-99m (Tc-99m) 
sestamibi single-photon emission computed tomographic 
(SPECT) myocardial perfusion imaging has incremental value 
for the diagnosis of coronary artery disease (2-4), and a recent 
study also reported incremental prognostic value (5). However, 
up to 40% of patients with chest pain are not able to exercise 
adequately (6), which may significantly reduce the detection of 
coronary disease. In contrast to exercise stress testing, dobu- 
tamine-atropine stress Tc-99m sestamibi SPECT imaging is 
not dependent on the level of exertion achieved. It is increas- 
From the Thoraxcentre and Department of Nuclear Medicine, University 
Hospital Rotterdam-Dijkzigt and Erasmus University, Rotterdam, The Nether- 
lands. This study was supported in part by funds from the Dutch Heart 
Foundation, The Hague, The Netherlands (Grant NHS 94.135) and Cairo 
University Hospital, Cairo, Egypt, and was presented in part at the 43rd Annual 
Scientific Session of the American College of Cardiology, Orlando, Florida, 
March 1996. 
Manuscript received September 12, 1995; revised manuscript received March 
14, 1996, accepted March 27, 1996. 
Address for correspondence: Dr. Paolo M. Fioretti, Thoraxcentre, Ba 302, 
Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. 
ingly used as an alternative stress technique (in particular, in 
patients with contraindications for vasodilator stress), and 
several investigators have reported that it is an accurate 
method for the detection of coronary artery disease (7-12). 
However, to date no study has assessed the prognostic value of 
this stress modality. Therefore, we studied alarge, unselected, 
consecutive group of patients with chest pain, unable to 
perform an adequate xercise test, with dobutamine-atropine 
Tc-99m sestamibi SPECT myocardial perfusion scintigraphy. 
We hypothesized that abnormal sestamibi scan results carry an 
increased risk of subsequent cardiac events and that this risk is 
proportional to the extent of the abnormalities and the pres- 
ence of reversible perfusion defects. 
Methods  
Patient selection. Over a 4-year period, between Novem- 
ber 1990 and October 1994, 418 consecutive patients with chest 
pain were referred to the nuclear cardiology laboratory at the 
Thoraxcentre for the evaluation of suspected myocardial isch- 
emia with dobutamine-atropine Tc-99m sestamibi SPECT 
imaging. All patients were unable to perform an adequate 
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exercise test, and none had undergone prior heart transplan- 
tation or had significant congenital or valvular heart disease, 
primary dilated cardiomyopathy, recent (<3 months) angio- 
plasty or unstable angina. Twenty-six patients with early elec- 
tive coronary revascularization within 60 days after stress 
testing were excluded from the analysis. None of these 26 
patients sustained a major cardiac event before coronary 
revascularization. The mean age of the remaining 392 patients 
was 60 _+ 12 years (range 23 to 85), 220 were men (56%), 190 
(48%) had a previous myocardial infarction, and 43 (11%) 
were known to have coronary artery disease without myocar- 
dial infarction. Ninety-five patients (24%) had typical angina, 
196 (50%) had atypical angina, and 101 (26%) had nonanginal 
chest pain. At the time of the study, 279 patients (71%) were 
receiving antianginal therapy, including beta-adrenergic block- 
ing agents in 161 patients (41%), administrated ither alone in 
43 (11%) or in combination with nitrates or calcium channel 
blocking agents, or both, in 118 patients (30%). 
Dobutamine-atropine stress test. After routine prepara- 
tion, a rest electrocardiogram (ECG) was obtained, intrave- 
nous access was secured and dobutamine was administered 
intravenously by an infusion pump. The infusion rate was 
10 p~g/kg body weight per rain for 3 rain, increasing by 10 IXg/kg 
per rain every 3 rain up to a maximum of 40 txg/kg per min. In 
patients not achieving 85% of their predicted maximal heart 
rate for their age and gender and without symptoms or signs of 
myocardial ischemia, atropine was administered in addition to 
the maximal dose of dobutamine, starting with 0.25 mg intra- 
venously and repeated up to a maximum of 1.0 mg within 4 rain 
with continuation of dobutamine infusion. Throughout dobut- 
amine infusion the ECG (3 leads) was continuously monitored 
and recorded (12 leads) at l-rain intervals. The level of ST 
segment shift was calculated, after signal averaging, by a 
computer-assisted system (Cardiovit CSG/12; Schiller, Baar, 
Switzerland). Blood pressure was measured and recorded by 
sphygmanometry every 3 rain. Reasons for interruption of the 
test were horizontal or downsloping ST segment depression 
>0.2 mV at an interval of 80 ms after the J point compared 
with baseline, ST segment elevation >0.1 mV in patients 
without previous myocardial infarction, severe angina, a symp- 
tomatic reduction in systolic blood pressure (>40 mm Hg from 
baseline), hypertension (blood pressure >240/120 mm Hg), 
significant cardiac tachyarrhythmias and any serious ide effect 
regarded as being due to dobutamine. Metoprolol was avail- 
able and used to reverse the effects of dobutamine if they did 
not revert spontaneously and quickly. 
Peffusion imaging. At peak stress, 370 MBq of Tc-99m 
sestamibi was injected intravenously while dobutamine infu- 
sion was continued for at least 1 rain. Stress scintigraphic 
images were acquired on average 1h after the termination of 
the dobutamine infusion. For rest studies, patients were rein- 
jected with 370 MBq of Tc-99m sestamibi at least 24 h after the 
stress study. Image acquisition was done with a Siemens 
Gammasonics single-head Orbiter camera. For each study six 
oblique (short-axis) slices were defined from the apex to the 
base and three sagittal (vertical long-axis) slices from the 
septum to the lateral wall. To compare the stress and rest 
studies, each of the six short-axis lices was divided into eight 
equal segments. The septal part of the two basal slices (four 
segments) was not evaluated because this region corresponds 
to the fibrous portion of the interventricular septum and 
normally exhibits reduced uptake. The apical region was 
assessed from the three central sagittal cross sections. A total 
of 47 segments/patient were analyzed. All tomographic views 
were reviewed in side-by-side pairs (stress and rest) by two 
experienced observers who were unaware of the patient's 
clinical history and other stress results. In case of disagree- 
ment, a third investigator reviewed the images and a majority 
decision was made. Subsequently, the 47 segments were 
grouped into six major segments: anterior, septum anterior, 
septum posterior, inferoposterior, lateral and apical. The 
myocardial uptake of radiotracer was evaluated visually (with 
the assistance ofcircumferential profiles analysis, including the 
normal values) for each of the six major segments during both 
rest and stress with a four-point scoring method (0 = normal; 
1 = equivocal or minimally reduced uptake; 2 = moderately 
reduced uptake; 3 = severely reduced or absent uptake). Scan 
results were initially characterized asabnormal or normal. Scan 
results were considered normal in the absence of any defect or 
the presence of only equivocal defects. Abnormal scan results 
were further classified as demonstrating fixed defects (rest 
perfusion defects) or reversible defects (perfusion defects dur- 
ing stress that partially or totally resolved at rest). To measure 
the influence of the extent and severity of the perfusion defect, 
a fixed defect score was calculated by summing the fixed 
perfusion defects, according to a 6 (extent) x 4 (severity) point 
model (range 0 to 18); similarly, a reversible defect score was 
calculated by summing the reversible peffusion defect scores. 
Subsequently, this latter score was corrected for stress level by 
dividing it by the following correction factor: percent arget 
heart rate reached times peak systolic blood pressure divided 
by 100. Patients with a zero reversible defect score were 
classified into a low stress level group (correction factor <1.6) 
and a high stress level group (correction factor >1.6). This 
cutoff value was chosen to classify patients with zero scores into 
two equally sized groups. 
Follow-up. Follow-up data were obtained over 22 + 13 
months (range 6 to 54) by outpatient clinic assessment, review 
of case notes and contacting the patient, general practitioner 
or other hospitals when necessary. Outcome events were 
cardiac death, nonfatal myocardial infarction and revascular- 
ization (coronary artery bypass graft surgery or percutaneous 
transluminal coronary angioplasty). Cardiac death was defined 
as a death temporally associated with a known or suspected 
acute myocardial infarction, life-threatening arrhythmia or 
pulmonary edema. Unexpected eath without an identified 
noncardiac ause and heart transplantation were also consid- 
ered as cardiac death. Occurrence of an acute myocardial 
infarction was confirmed using standard clinical and ECG 
criteria and when total creatine kinase (CK) enzyme levels 
exceeded twice normal. Hard cardiac events (cardiac death 
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Table 1. Clinical and Stress Test Data for 392 Study Patients (hard 
cardiac events) 
Table 2. Clinical and Stress Test Data for 392 Study Patients (all 
cardiac events) 
No Cardiac No Cardiac 
Event Cardiac Event p Events Cardiac Events p 
(n = 348) (n = 44) Value (n = 314) (n = 78) Value 
Age >70 yr 64 (18%) 12 (27%) 0.0804 Age >70 yr 61 (19%) 15 (19%) 0.5156 
Male 187 (54%) 33 (75%) 0.0037 Male I67 (53%) 53 (68%) 0.0094 
Risk factors Risk factors 
Diabetes 50 (14%) 9 (20%) 0.1440 Diabetes 46 (15%) 13 (17%) 0.3281 
Hypercholesterolemia 89 (26%) 9 (20%) 0.7698 Hypercholesterolemia 80 (25%) 18 (23%) 0.6692 
Hypertension 146 (42%) 22 (50%) 0.1551 Hypertension 132 (42%) 36 (46%) 0.2557 
Smoking 96 (28%) 15 (34%) 0.2958 Smoking 87 (28%) 24 (31%) 0.2958 
History History 
Myocardial infarction 160 (46%) 30 (68%) 0.0028 Myocardial infarction 138 (44%) 52 (67%) 0.0002 
Congestive h art failure 59 (17%) 17 (39%) 0.0003 Congestive heart failure 53 (17%) 23 (29%) 0.0059 
Revascularization 105 (30%) 17 (39%) 0.i269 Revascularization 88 (28%) 34 (44%) 0.0040 
Typical angina 80 (23%) 15 (34%) 0.0529 Typical angina 61 (19%) 34 (44%) 0.0000 
Stress test Stress test 
Angina during stress 86 (25%) 16 (36%) 0.0487 Angina during stress 73 (23%) 29 (37%) 0.0061 
ST-T wave changes 57 (16%) 11 (25%) 0.0776 ST-T wave changes 47 (15%) 21 (27%) 0.0063 
MIBI scan pattern MIBI scan pattern 
Abnormal 220 (63%) 42 (95%) 0.0000 Abnormal 190 (61%) 72 (92%) 0.0000 
Fixed defect 169 (49%) 33 (75%) 0.0005 Fixed defect 146 (46%) 56 (72%) 0.0000 
Reversible defect 130 (37%) 30 (68%) 0.0000 Reversible defect 108 (34%) 52 (67%) 0.0000 
Data presented are number (%) of patients. MIBI = technetium-99m 
sestamibi. 
Format as in Table 1. 
and nonfatal myocardial infarction) and all cardiac events 
(hard events or revascularization) were analyzed as end points. 
Statistical analysis. Values were expressed as mean 
value _+ SD, when appropriate. Comparison (two-tailed) of 
patients with and without cardiac events was performed with 
the Student test for continuous variables and chi-square test 
for discrete variables. Differences of p < 0.05 were considered 
significant. Multivariate logistic regression using the BMDP 
package (13) was performed to identify factors that were 
related to events. A forward and backward stepping algorithm 
was used with p < 0.05 to identify the independent predictors 
for both hard and all events. Baseline variables tested were the 
clinical and stress test variables, as displayed in Tables 1 and 2. 
Odds ratio and 95% confidence intervals were calculated for 
variables used in the multivariate model. Kaplan-Meier life- 
table estimates of infarction-free survival (survival without 
cardiac death or nonfatal myocardial infarction) and event- 
free survival (survival without cardiac death, nonfatal myocar- 
dial infarction or revascularization) were used to summarize 
the follow-up experience and to clarify presentation. 
Resu l ts  
Dobutamine-atropine stress test. Hemodynamic results, 
endpoints and side effects. The maximal dobutamine dose used 
was 10 /xg/kg per rain in 1 patient, 20 /xg/kg per min in 5 
patients, 30/xg/kg per min in 56 patients and 40/~g/kg per rain 
in 330 patients. Atropine was added in 169 patients (43%) and 
was more often used in patients receiving beta-blockers (108 of 
161 with vs. 61 of 231 without beta-blockers, p < 0.0001). In 
the overall group, dobutamine-atropine i creased heart rate by 
65 + 15 beats/rain to a peak heart rate of 135 + 17 beats/rain, 
systolic blood pressure by 10 _+ 27 mm Hg to a peak pressure 
of 148 + 31 mm Hg and rate-pressure product by 10,332 + 
3,764 mm Hg × beats/rain to a peak rate-pressure product of 
20,025 _~ 4,848 mm Hg x beats/rain. 
Target heart rate (85% of maximum for age and gender) 
was not reached in 77 tests (20%) either after the maximal 
dobutamine-atropine dose had been given in 28 patients (7%) 
or when prematurely stopping the test in 49 patients (14%). 
The test was prematurely stopped in patients because of angina 
in 33, ST segment changes in 3, hypertension i  3, symptomatic 
hypotension in 4, nonsustained ventricular tachycardia in 3, 
anxiety in 2 and headache in 1. Most patients not reaching their 
target heart rate because of an insufficient dose of dobutamine- 
atropine were on beta-blockers (22 of 28 with vs. 6 of 28 
without beta-blockers, p < 0.0001). Nondiagnostic tests (target 
heart rate not reached in the absence of reversible perfusion 
defects) were present in 30 patients (8%). Tachyarrhythmias 
during dobutamine infusion or recovery were not uncommon; 
10 patients (3%) had supraventricular tachycardia, and 17 
(4%) had (nonsustained) ventricular tachycardia. Apart from 
angina (induced in 102 patients [26%]), side effects were 
unusual and minor (side effects occurring in >5% of patients 
were chills in 5%, headache in 6% and nausea in 5%). Three 
hundred twenty-two patients (82%) were free of any side effect 
(not considering angina). 
Distribution of imaging patterns. One hundred thirty pa- 
tients (33%) had normal (or equivocal in 30) scan results, 
and 262 (67%) had abnormal results. Scan abnormalities 
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Figure 1. Kaplan-Meier infarction-free survival curves in patients with 
normal scan results, fixed defects alone, reversible defects alone and 
mixed defects. Infarction-flee survival was significantly lower in pa- 
tients with fixed defects alone (p < 0.001), reversible defects alone 
(p < 0.0001) and mixed efects (p < 0.0001) than in those with normal 
scan results. The number of patients available for follow-up at 0, 1, 2 
and 3 years, respectively, was 130, 109, 46 and 28 in the subset with 
normal scan results; 102, 74, 32 and 17 in the subset with fixed defects 
alone; 60, 48, 26 and 9 in the subset with reversible defects alone; and 
100, 76, 34 and 20 in the subset with mixed efects. 
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Figure 2. Kaplan-Meier event-flee survival curves in patients with 
normal scan results, fixed defects alone, reversible defects alone and 
mixed defects. Event-flee survival was significantly lower in patients 
with fixed defects alone (p < 0.00t), reversible defects alone (p < 
0.0001) and mixed efects (p < 0.0001) than in those with normal scan 
results. The number of patients available for follow-up at 0, 1, 2 and 3 
years, respectively, was 130, 105, 44 and 27 in the subset with normal 
scan results; 102, 69, 29 and 15 in the subset with fixed defects alone; 
60, 39, 23 and 8 in the subset with reversible defects alone; and 100, 62, 
25 and 15 in the subset with mixed efects. 
included fixed defects alone in 102 patients (26%), reversible 
perfusion defects alone in 60 (15%) and fixed plus reversible 
defects (or partially reversible defects) in 100 (26%). In total, 
202 patients (52%) had fixed defects, and 160 (41%) had 
reversible perfusion defects. 
Clinical outcome. The mean follow-up period was 22 +_ 13 
months for patients with and without reversible defects. Eigh- 
teen patients (5%) had an "incomplete" follow-up, 13 because 
of noncardiac death (cancer in 8, pneumonia in 2, acquired 
immune deficiency syndrome in 1, complicated hip fracture in 
1 and myelodysplasia in 1) and 5 because of geographic 
relocation. Cardiac events occurred in 78 patients, 44 of whom 
had hard cardiac events (nonfatal myocardial infarction in 17 
and cardiac death in 27), 
Prediction of events from clinical and stress test results. 
Univariate analysis. In Tables 1 and 2 the clinical and stress 
test data in patients with and without hard and all cardiac 
events are summarized. Clinical variables associated with hard 
cardiac events were male gender, a history of myocardial 
infarction and a history of congestive heart failure. Clinical 
variables associated with all cardiac events were male gender 
and history of myocardial infarction, coronary revasculariza- 
tion, congestive heart failure or typical angina. Apart from 
peak heart rate in patients with any versus without any event 
(132 _+ 18 vs. 136 + 17, p < 0.05), no hemodynamic variable 
(rest and peak heart rate, blood pressure and rate-pressure 
product) was associated with an increased rate of hard or all 
cardiac events. Of the other stress test variables, stress-induced 
angina was associated with both hard and all events and ST-T 
wave changes were only associated with all cardiac events. 
Sestamibi scan patterns associated with both hard and all 
cardiac events were the presence of abnormalities on the scan 
(any perfusion abnormality), fixed perfusion defects and re- 
versible perfusion defects. 
The infarction-free and event-flee survival curves in pa- 
tients with normal scan results, fixed defects alone, reversible 
defects alone and mixed (fixed and reversible) defects are 
depicted in Figures 1 and 2. Normal scan results were associ- 
ated with a favorable prognosis over the follow-up eriod, with 
an annual event rate of 0.8% for hard events and 2.5% for all 
events. In contrast, patients with fixed defects alone, reversible 
defects alone and fixed plus reversible defects had a signifi- 
cantly increased cardiac event rate of 6.8%, 8.1% and 11.6%, 
respectively, for hard events, and 11.4%, 14.5% and 19.9%, 
respectively, for all events. Compared with normal scan results, 
reversible perfusion defects alone increased the risk for future 
hard events tenfold and for all events ixfold. Compared with 
fixed defects alone, fixed plus reversible perfusion defects 
increased the risk for both hard events and all events twofold. 
Multivariate analysis, addition of perfusion scintigraphy to 
clinical data. Tables 3 and 4 summarize the results of univar- 
late and multivariate (stepwise logistic regression) analysis of 
clinical and stress test data to predict subsequent hard and all 
cardiac events. Multivariate analysis of clinical variables (Table 
3, Clinical Data) revealed male gender (odds ratio [OR] 2.3, 
95% confidence interval [CI] 1.1 to 4.7) and a history of 
congestive heart failure (OR 2.7, 95% CI 1.4 to 5.4) as 
independent predictors of subsequent hard cardiac events. The 
addition of scan patterns to this analysis was performed 
according to two different models. In the first model (Table 3, 
Model I) the only scan pattern variable entered was the 
presence of an "abnormal scan" (any abnormality), and in the 
second model (Table 3, Model II) the presence of a fixed or 
reversible perfusion defect was separately included. A history 
of congestive heart failure (OR 2.0, 95% CI 1.0 to 3.9) and 
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Table 3. Association by Univariate and Multivariate Analysis of Clinical and Stress Test Data With 
Hard Cardiac Events: Odds Ratios (95% confidence intervals) 
Multivariate Analysis of Clinical and Stress Test Data 
Univariate Clinical 
Analysis Data Model I Model II 
Clinical data 
Age >70 yr 1.6 (0.8-3.4)* 
Male 2.6 (1.3-5.3) 
History of infarction 2.5 (1.3-4.9) 
History of revascularization 1.5 (0.8-2.8)* 
History of heart failure 3.1 (1.6-6.0) 
Typical angina 1.7 (0.9-3.4)* 
Stress test data 
Angina 1.7 (0.9-3.4)* 
ST-T wave changes 1.7 (0.8-3.6)* 
Scan abnormalities 12.2 (2.9-51.3) 
Fixed defect 3.2 (1.6-6.5) 
Reversible defect 3.6 (1.8-7.0) 
* * 2.1 (1 .0 -4 .4 )  
2.3 (1.1-4.7) * * 
2.7 (1.4-5.4) 2.0 (1.0-3.9) 2.6 (1.3-5.2) 
q 10.0 (2.3-43.0) 
- -  3.2 (1 .6 -6 .4 )  
*p value not significant. In model I, scan variables included scan abnormalities. Inmodel II, pattern variables included 
fixed defect and reversible defect and excluded scan abnormalities. - - = variable xcluded. 
abnormal scan results (OR 10.0, 95% CI 2.3 to 43.0) in model 
I were independent predictors of hard cardiac events. In model 
II, older age (OR 2.1, 95% CI 1.0 to 4.4) and reversible 
perfusion defects (OR 3.2, 95% CI 1.6 to 6.4) were indepen- 
dent predictors of hard cardiac events. 
For all cardiac events (Table 4), the clinical variables 
history of myocardial infarction (OR 2.9, 95% CI 1.7 to 5.1) 
and typical angina (OR 3.3, 95% CI 1.9 to 5.7) were indepen- 
dent predictors in the clinical model. In model I, independent 
predictors were history of typical angina (OR 3.2, 95% CI 1.9 
to 5.6) and abnormal scan results (OR 7.9, 95% CI, 3.3 to 
18.9). In model II, a history of typical angina (OR 2.9, 95% CI 
1.7 to 5.1), fixed perfusion defects (OR 2.5, 95% CI 1.4 to 4.4) 
and reversible perfusion defects (OR 3.1, 95% CI 1.8 to 5.4) 
were independent predictors of all cardiac events. 
Extent and severity of perfusion defects and prognosis. As 
described in the legend to Figure 3, 162 patients had a fixed 
perfusion defect score of zero, 114 had a score of one to three, 
70 of four to six, 27 of seven to nine and 19 of ten or higher. At 
the end of the follow-up period, the annual hard event rate for 
patients with these fixed perfusion defect scores were 3.3% 
(mean follow-up 23 months), 5.0% (23 months), 8.1% (21 
months), 11.5% (23 months) and 36.4% (12 months), respec- 
tively. For all events, these numbers were 5.6%, 13.2%, 13.0%, 
17.2% and 36.4%, respectively, As seen in the legend to Figure 
4, 100 patients had a stress level corrected reversible perfusion 
defect zero score with "high stress" (correction factor >1.6), 
100 patients had a zero score with "low stress" (correction 
factor <1.6), 109 had a score of one or two, 62 of three or four 
and 21 of five or higher. At the end of the follow-up eriod, the 
annual hard event rate for the different reversible perfusion 
defect scores was 2.1% (mean follow-up 21 months), 5.0% (23 
months), 5.5% (22 months), 13.0% (22 months) and 14.6% (20 
months), respectively. For all events, these numbers were 
4.2%, 7.8%, 11.5%, 20.9% and 26.3%, respectively. 
Discussion 
The present study addressed the prognostic value of 
dobutamine-atropine stress Tc-99m sestamibi SPECT imaging 
in patients referred with chest pain and suspected myocardial 
ischemia. Dobutamine stress is frequently used in conjunction 
with echocardiography and has been shown to provide impor- 
tant prognostic information (14). However, to our knowledge, 
no information is available when dobutamine stress is used in 
conjunction with perfusion imaging. The main finding of this 
study is that, in patients with chest pain who are unable to 
perform an adequate xercise test, the test provides useful 
prognostic information in addition to clinical data. 
Stress technique. Dobutamine is a synthetic sympathomi- 
metic amine that stimulates beta1, beta2 and alpha 1 receptors. 
As a result, there is a marked inotropic response (mediated by 
both alpha I and beta I receptors), a modest chronotropic 
response (mediated by beta I receptors) and a minor increase 
in systolic blood pressure (due to alpha l- and betal-mediated 
increase in cardiac output and relative stable peripheral vas- 
culature tonus, mediated by alpha 1 vasoconstriction a d beta2 
vasodilation) (15). As a result of this augmentation fmyocar- 
dial contractility, heart rate, left ventricular pressure and wall 
stress, more oxygen is required. Normally a dose-related 
increase in subepicardial nd subendocardial blood flow occurs 
within myocardium supplied by normal coronary arteries 
(16,17). However, blood flow increases minimally within vas- 
cular beds supplied by significantly stenosed arteries, with most 
of the increase occurring within the subepicardium rather than 
the subendocardium (16). This heterogeneity in myocardial 
blood flow between ormal and abnormal perfused areas can 
be visualized by Tc-99m sestamibi myocardial perfusion scin- 
tigraphy. 
Although direct vasodilators (dipyridamole and adenosine) 
are believed to be superior in creating blood flow heterogene- 
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Tab le  4. Association by Univariate and Multivariate Analysis of Clinical and Stress Test Data With All 
Cardiac Events: Odds Ratios (95% confidence intervals) 
Multivariate Analysis of Clinical and Stress Test Data 
Univariate Clinical 
Analysis Data Model I Model I1 
Clinical data 
Age >70 yr 1.0 (0.5-1.9)* 
Male 1.9 (1.1-3.2) 
History of infarction 2.5 (1.5-4.3) 
History of revascularization 2.0 (1,2-3.3) 
History of heart failure 2.1 (l.2-3.6) 
Typical angina 3.2 (l.9-5.4) 
Stress test data 
Angina 2.0 (1.2-3.3) 
ST-T wave changes 2.1 (1.2-3.8) 
Abnormal scan 7.8 (3.3-18.6) 
Fixed defect 2.9 (1.7-5.0) 
Reversible defect 3.8 (2.3-65) 
2.7 (1.6-4.5) * * 
3.3 (1.9-5.7) 3.2 (1.9-5.6) 2.9 (1.7-5.1) 
- -  7.9  (3 .3 -18 .9 )  - -  
- -  - -  2.5 (1.4-4.4) 
- -  - -  3.1 (1.8-5.4) 
Format as in Table 3. 
ity (16), dobutamine Tc-99m sestamibi SPECT imaging has a 
good accuracy for the detection of coronary artery disease 
when used in conjunction with perfusion scintigraphic tech- 
niques. Pooled data from six published studies in 380 patients 
(7-12) show a sensitivity of 84% and a specificity of 71% for 
the detection of coronary artery disease. Moreover, a direct 
comparison by Marwick et al. (18) between vasodilator and 
dobutamine for Tc-99m sestamibi myocardial perfusion scin- 
tigraphy in 97 patients yielded similar diagnostic accuracies of 
the two stress agents. Thus, dobutamine can be regarded as an 
excellent alternative stress agent in patients unable to perform 
adequate xercise, in particular in those patients with relative 
contraindications for vasodilator stress (mainly patients with 
obstructive airway disease) or in patients who have ingested 
caffeine or aminophylline shortly before undergoing myocar- 
dial perfusion stress imaging. 
Safety and feasibility. As shown in other (echocardio- 
graphic) studies (19-21), dobutamine-atropine stress is a safe 
Figure 3. Histogram showing the annual event rate for hard events 
(open bars) and all events (hatched bars) according to extent and 
severity score of fixed perfusion defects. The number of patients in 
each category was 162, 114, 70, 27 and 19, respectively. 
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and feasible stress method in patients with chest pain. In this 
study, there were no serious ide effects like sustained ventric- 
ular tachycardia, ventricular fibrillation, myocardial infarction 
or death. The feasibility of the test was also high, as only 30 
patients (8%) had a nondiagnostic test and 322 patients (82%) 
were free of any side effect. 
Prognostic value. The present study indicates that patients 
at greater isk for hard or all cardiac events can be identified 
from a stable chest pain population by virtue of their clinical 
(older age, male gender and history of myocardial infarction, 
revascularization procedures, congestive heart failure or typi- 
cal angina) and scintigraphic (abnormal scan results, fixed or 
reversible perfusion defects) profile. 
The single most important independent predictor of subse- 
quent events was abnormalities on the perfusion study (any 
abnormality); such an abnormal finding increased the risk for 
subsequent hard cardiac events tenfold and for all events 
Figure 4. Histogram showing the annual event rate for hard events 
(open bars) and all events (hatched bars) according to the (stress level 
[high/low] corrected) extent and severity score of reversible perfusion 
defects. The number of patients in each category was 100, 100, 109, 62 
and 21, respectively. 
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eightfold. A normal scan conferred a good prognosis and 
identified 33% of the subgroup that was at a very low risk for 
hard events (annual event rate 0.8%) and low risk for all events 
(annual event rate 2.5%). Furthermore, an ischemic pattern 
provided additional, independent prognostic value. Compared 
with patients without ischemia, these patients had a threefold 
increased risk for both hard and all events. 
Prognostic value according to extent and severity of perfn- 
sion defects. This study clearly shows a direct relation between 
the extent and severity of the perfusion defects and prognosis. 
Several other investigators, using mainly exercise planar or 
SPECT thallium-201 imaging, have described a relation be- 
tween the extent of the perfusion defect and subsequent 
coronary events (22-25). In particular, the degree of hypoper- 
fusion on SPECT imaging, with its ability to provide much finer 
segmental analysis, avoiding the problem of superimposition 
that occurs with planar imaging, is directly related to the extent 
of the myocardium either already destroyed by a previous 
infarct or ischemic but viable and at risk for necrosis. Although 
the extent of coronary artery disease is an important prognostic 
indicator (26), sestamibi SPECT imaging represents he func- 
tional significance of the stenoses, a factor which may be 
superior to angiographic data (27). 
Comparison with other sestamibi studies. In comparable 
patient populations, most published data regarding Tc-99m 
sestamibi in combination with other stress techniques found 
striking similar results. Stratmann et al. (5) reported the 
prognostic value of exercise Tc-99m sestamibi imaging in 521 
patients. During multivariate analysis, abnormal scan results 
(OR 11.9, 95% CI 1.6 to 89.4) and reversible defects (OR 2.9, 
95% CI 1.2 to 7.0) were the only independent predictors of 
hard cardiac events. Patients with normal scan results had an 
annual event rate of 0.4%. In another study by Stratmann et al. 
(28), comparable prognostic results were reported for dipyrid- 
amole Tc-99m sestamibi imaging in 308 patients. Patients with 
normal scan results had an annual event (unstable angina, 
nonfatal myocardial infarction or cardiac death) rate of 1.7%. 
Several studies focused on the predictive value of normal 
Tc-99m sestamibi imaging for the prediction of hard cardiac 
events. Both exercise (29,30) and dipyridamole (31) studies 
found annual event rates <1%. 
Study limitations. Although recurrent angina may be a 
marker of ischemia, the subjective nature of this symptom, as 
well as influence by medication usage and other factors, makes 
this a potential unreliable end point of prognostic testing. 
Furthermore, the decision to perform coronary arteriography 
and subsequent coronary artery bypass graft surgery is fre- 
quently influenced by individual physicians' biases and may 
also be affected by the presence of abnormal findings on the 
stress study. Therefore, we excluded patients with early elec- 
tive revascularizations and we analyzed the "hard" events 
(nonfatal myocardial infarction and cardiac-related death) 
separately. Because there is limited angiographic nformation 
available, our study does not permit assessment of the speci- 
ficity and sensitivity of dobutamine stress sestamibi perfusion 
scintigraphy for the detection of significant coronary artery 
disease. 
Increased lung radiotracer uptake, a prognostic marker in 
previous cintigraphic studies (32) was also not available in the 
current Tc-99m sestamibi tomographic nvestigation. The in- 
terpretation of the SPECT images was semiquantitative. This 
type of analysis, however, is still the most frequently used in 
daily clinical practice. Antianginal medications were not rou- 
tinely withheld before stress testing; we believe this also 
reflects daily clinical practice. 
Conclusions. In patients unable to exercise adequately, 
with chest pain and suspected or known coronary disease, 
dobutamine-atropine stress Tc-99m sestamibi SPECT perfu- 
sion imaging is a safe and feasible stress technique. The test 
provides useful prognostic information, probably comparable 
with exercise or dipyridamole stress Tc-99m sestamibi imaging 
studies. The single most important independent predictor of 
both hard (nonfatal myocardial infarction or cardiac death) 
and all (hard events or revascularization procedures) cardiac 
events is an abnormal perfusion pattern (any abnormality); the 
presence of a reversible perfusion defect provides additional, 
independent prognostic nformation. Moreover, the extent and 
severity of the perfusion defects are major determinants for 
prognosis. 
We thank Joyce Postma-Tjoa, nuclear medicine technician, for invaluable help in 
maintaining the data base. 
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